Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H28N |
Molecular Weight | 306.4644 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC[N+]1(CC)CCC(C1C)=C(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=ZYEPZINLLPPBMI-UHFFFAOYSA-N
InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1
Molecular Formula | C22H28N |
Molecular Weight | 306.4644 |
Charge | 1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including http://www.rlsnet.ru/tn_index_id_6544.htm
Curator's Comment: description was created based on several sources, including http://www.rlsnet.ru/tn_index_id_6544.htm
Prifinium bromide is antimuscarinic drug, which has antispasmodic, antiemetic effect. Prifinium bromideis approved for pain relief in Russia, Indonesia, Iraq, Tunisia and other countries.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?D01377 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Reyabal Approved UsePain due to spasm and hypermotility of the gastrointestinal tract: gastritis, gastroduodenal ulcer, enteritis, colitis, post-gastrectomy syndrome and irritable colon. Pain due to spasm and dyskinesia of the bile duct cholecystitis, and choleithiasis. Pain due to pancreatitis. Pain due to spasm of urinary tract, lithureteria, vesical tenesmus, cystitis and pyelitis. |
|||
Secondary | Reyabal Approved UsePremedication for gastric endoscopy and gastrointestinal radiography. |
|||
Sources: http://www.rlsnet.ru/tn_index_id_6544.htm |
Primary | Riabal Approved UseVomiting (functional spasms in infants and children after feeding, with acute gastroenteritis, febrile conditions, with intracranial hypertension, after radiation therapy, with intolerance of medicines). |
Sample Use Guides
Tablets of Reyabal, containing 325 mg Paracetamol and 30 mg Prifinium bromide, are indicated against pain 1-2 tablets a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5299979
Prifinium bromide depressed the amplitude of muscle contraction induced by electrical stimulation of the phrenic nerve at a concentration of 50 ug/ml, while large concentrations of 100 ug/ml produced no change on muscle contraction induced by direct stimulation of the muscle.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:19:14 GMT 2023
by
admin
on
Fri Dec 15 16:19:14 GMT 2023
|
Record UNII |
3C7TTK1K7K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10236-81-4
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
3C7TTK1K7K
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
233-568-5
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
2264
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
DB13254
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
DTXSID70859880
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
SUB04037MIG
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
C84105
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
4905
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
100000085098
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | |||
|
236174
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
C084641
Created by
admin on Fri Dec 15 16:19:14 GMT 2023 , Edited by admin on Fri Dec 15 16:19:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |